Ask AI
ProCE Banner Activity

ASC2ESCALATE: Phase II Trial of Asciminib in Patients With CML-CP After 1 TKI

Conference Coverage
Slideset

In this updated interim analysis of the phase II ASC2ESCALATE trial, the use of asciminib as second-line treatment for patients with CML-CP continued to be effective and tolerable at Week 24.

Released: June 02, 2025

Expiration: December 01, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation